Testosterone gel (transdermal)

Daily transdermal testosterone, dosed by pump actuations or sachets rather than injection volume.

Medications & hormones

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Testosterone gel (transdermal)

Daily transdermal testosterone, dosed by pump actuations or sachets rather than injection volume.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Testosterone gel is approved by the US FDA as testosterone replacement therapy in males with primary hypogonadism or hypogonadotropic hypogonadism. Both linked labels carry a boxed warning that children exposed to treated skin have developed signs of virilization. The 2025 label removed its cardiovascular-risk warning and added warnings on venous blood clots and blood pressure increases. Labels also state that different topical products can give different testosterone exposure. This is regulator-approved labelling, not trial evidence.

Benefits reported in the imported source

Testosterone replacement in males with diagnosed hypogonadism.

Risks and limits

Boxed warning: children exposed to treated skin have developed signs of virilization
The 2025 label dropped the cardiovascular warning and added blood clot and blood pressure warnings
Different topical products can give different testosterone exposure

Source bottom line: Approved labelling rather than trial evidence: it treats diagnosed hypogonadism and carries a boxed skin-transfer warning.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Males with primary hypogonadism or hypogonadotropic hypogonadism, per the US label

Reported regimen: 50 mg of testosterone applied once daily to clean dry skin of the shoulders, upper arms and/or abdomen, adjustable between 25 mg and 100 mg daily
Duration: Ongoing, per the label; dose changes after at least 14 days
Reported outcome: Approved as testosterone replacement therapy; the boxed warning records virilization in children exposed to treated skin.
Source: AndroGel (testosterone) gel FDA label

Claim provenance

evidence.json#/catalog:hormone:testosterone-gel/protocols/0

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Unverified imported account — Pharmacology of testosterone replacement therapy preparations

An imported authored paraphrase, not a quotation or a recommended protocol.

Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.

Imported wording: FDA-approved testosterone gel formulations begin at 40–60 mg daily applied topically, with dose titration in 10–25 mg increments based on serum testosterone levels, reaching maximum doses of 100–120 mg daily depending on the specific gel product.

Pharmacology of testosterone replacement therapy preparations

Pharmacokinetic context

Historical half-life estimate: 2 hours. Transdermal; steady state in 24-48 h Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

Snapshot provenance

Source ID: catalog:hormone:testosterone-gel. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.

Related entries and components

None listed.